© Reuters Search top! Do you pay attention to viral myocarditis after “Yang Guo”? These A-share pharmaceutical companies distribute related businesses
News from the December 31 Associated Financial Press (edited by Li Chen)“My heartbeat is a bit fast, do I have to go to the hospital?” “My heart rate exceeds 120 beats per minute, do I have myocarditis?” Recently, many patients who have been infected with the new coronavirus have left messages on the Internet stating that they have symptoms such as rapid heartbeat, suspect myocarditis, and ask if medical help is needed.The topic “Beware of viral myocarditis after Yang’s passage” has become the number one search list。
Recently, the cases of myocarditis caused by the novel coronavirus have aroused the attention of all the people. Because young people are susceptible to myocarditis, they are also more concerned about the risk of myocarditis after COVID-19 infection and recovery. According to increasing reports, there is an individual susceptibility to myocarditis. If a young person has never had myocarditis due to a cold before the age of 25, he need not worry too much about suffering from a new corona-related myocarditis.
Myocarditis is an inflammatory lesion of the myocardium, which can be caused by infections (such as viruses, bacteria or fungi) or by non-infectious factors (such as autoimmune diseases, etc.). Clinically, myocarditis is mainly caused by a viral infection and the common cold can also be induced.
According to the incomplete settlement of the Financial Associated Press, listed companies engaged in related activities for the treatment of myocarditis are mainlyXinguang Pharmaceutical, Dali Pharmaceutical, Tuoxin Pharmaceutical, Yisheng Pharmaceutical, etc.The specific activity is as follows：
On December 30, Xinguang Pharmaceutical responded on Interactive Easy that, according to the literature, the company’s productsTreatment of viral myocarditis with Huangqi Shengmai decoctionClinically it has received satisfactory results.
Tuoxin Pharmaceutical responded on Dec. 29 that the subsidiary companyCyclic Adenosine Monophosphate API are used to produce Cyclic Adenosine Monophosphate finished products for the treatment ofangina pectoris, myocardial infarction,Myocarditisand cardiogenic shock. It has a certain effect on improving the symptoms such as palpitations, shortness of breath and chest tightness of rheumatic heart disease.
On December 28, Yisheng Pharmaceutical responded on Interactive Easy, saying that after consulting the professional literature,Levocarnitine combined with Qingkailing injection has significant effect in the treatment of viral myocarditisthe company produces Qingkailing injection.
According to the data, Dali pharmaceuticalsShenmai injection is mainly used for the treatment of viral myocarditisand other diseases.
Shen Chengxing, director of the Department of Cardiovascular Medicine of the Sixth People’s Hospital Affiliated to Shanghai Jiaotong University, pointed out in an interview with a reporter of The Paper that foreign studies have shown that the incidence of myocarditis in patients with new crowns is between the 2‰ and 4‰. The vast majority of myocarditis can heal itself, the severe case rate is extremely low, and the early treatment effect is also very good.Instead, we should beware of “myocarditis phobia”, which will lead to the aggravation of new corona symptoms。
It is worth noting that Shen Chengxing said that recently the number of outpatients in his cardiology department has been three to four hundred a day, and about half of them are seeking examination to rule out myocarditis after new crown infection. . say 99% of them can be excluded.”
